TOREMIFENE INCREASES BONE MINERAL DENSITY IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER: INTERIM ANALYSIS OF A MULTICENTER PHASE 3 CLINICAL STUDY

PURPOSE: To evaluate the effects of toremifene on bone mineral density (BMD), a surrogate for fracture risk, in men receiving androgen deprivation therapy (ADT) for prostate cancer. MATERIALS AND METHODS: In an ongoing, multicenter, Phase 3 fracture prevention study, 1392 men ≥ 50 years old with pro...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Smith, MR, Malkowicz, S Bruce, Chu, F, Forrest, J, Price, D, Sieber, P, Barnette, KG, Rodriguez, D, Steiner, MS
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2007
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3090686/
https://ncbi.nlm.nih.gov/pubmed/18001802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2007.08.137
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak